case_images: PMC11317420_01
case_images: The assessments of MG-ADL scores from starting the efgartigimod treatment to eight weeks after treatment. (MG-ADL, myasthenia gravis-activities of daily living).
case_images: fimmu-15-1418503-g001.jpg
case_images: PMC11317420_01_fimmu-15-1418503-g001.jpg
case_images: f1
case_images: The MG-ADL score reduced from 15.6 +- 4.4 at the baseline to 3.4 +- 2.2 after one cycle of efgartigimod ( Figure 1 ).
case_images: Repeated measurements of the serum IgG (n=8) and anti-AChR antibody levels (n=6) before- and after one cycle of efgartigimod treatment.
case_images: fimmu-15-1418503-g002.jpg
case_images: PMC11317420_01_fimmu-15-1418503-g002.jpg
case_images: f2
case_images: Anti-AChR antibody levels were reduced by 42.0% from baseline values of 29.5 +- 22.9 nmol/L to 17.1 +- 8.2 nmol/L (p = 0.305). ( Figure 2 ).